leider nur english, jedoch sehr interessant, danke Grenke für den Tipp
denke könnte was werden
PharmaNetics Announces Date of Hearing in Lawsuit against Aventis; Company Reduces Workforce
RALEIGH, N.C., Jan 23, 2004 (BUSINESS WIRE) -- PharmaNetics, Inc. (NASDAQ-SCM:
PHAR), a leader in theranostic management specializing in managing the delivery
of therapeutics affecting coagulation, today announced that the Federal Fourth
Circuit Court will hold a hearing on March 22 - 24, 2004, in New Bern, North
Carolina, relating to PharmaNetics lawsuit against Aventis Pharmaceuticals,
Inc., the wholly owned subsidiary of French pharmaceutical company, Aventis.
The Company also announced that it is reducing its workforce by an additional 17
people to 38 employees. The action is taken to allow the Company to maintain its
manufacturing capability as the Company continues to review strategic
alternatives with its investment banker, Davenport & Company.
PharmaNetics, Inc., a leading biotech company, conceived the term
"theranostics," defining an emerging field of medicine that enables physicians
to monitor the effect of antithrombotic agents in patients being treated for
angina, myocardial infarction (heart attack), stroke, and pulmonary and arterial
emboli. The Company develops, manufactures and markets rapid turnaround
diagnostics to assess blood clot formation and dissolution. PharmaNetics
develops tests based on its proprietary, dry chemistry Thrombolytic Assessment
System. Its principal target market is the management of powerful new drug
compounds, some of which may have narrow therapeutic ranges, as well as
monitoring routine anticoagulants.
This press release contains forward-looking statements regarding future events
and the future performance of PharmaNetics that involve risks and uncertainties
that could cause actual results to differ materially from those projected in the
forward-looking statements. These risks and uncertainties include risks related
to market acceptance, clinical trials and dependence on third party distributors
and collaborative partners, including, in particular with regard to the legal
proceedings commenced against its development partner, Aventis Pharmaceuticals,
which action includes without limitation the following specific risks: material
monetary costs associated with the litigation, even if successful; uncertainty
of obtaining a favorable outcome; the potentially significant harm to
PharmaNetics' business and financial condition and prospects if it is not
successful in timely prosecuting the litigation; jeopardizing strategic
relationships with other existing or potential collaborative partners; harmful
delays in meeting sales objectives, even if the litigation is successful; and
disruption of management time and resources to pursue the litigation.
Information concerning these and other of the factors that could cause results
to differ materially from those in the forward-looking statements is contained
in the Company's filings with the Securities and Exchange Commission, including
Form 10-K, Form 10-Q and Form 8-K reports.
|
|
2
Thread abonnieren
